Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,474 shares of the medical equipment provider’s stock after selling 157 shares during the period. Stratos Wealth Partners LTD.’s holdings in Lantheus were worth $221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in LNTH. Janus Henderson Group PLC lifted its holdings in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after buying an additional 257,022 shares during the period. Geode Capital Management LLC raised its position in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares in the last quarter. Reinhart Partners LLC. lifted its holdings in Lantheus by 9.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after acquiring an additional 123,282 shares during the period. Swedbank AB boosted its position in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC grew its stake in shares of Lantheus by 6.1% during the 3rd quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock worth $73,629,000 after purchasing an additional 38,776 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on LNTH. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial restated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Stock Down 0.2 %

Shares of LNTH opened at $81.96 on Friday. The firm’s fifty day moving average is $91.76 and its two-hundred day moving average is $98.13. The stock has a market cap of $5.70 billion, a PE ratio of 13.64 and a beta of 0.44. Lantheus Holdings, Inc. has a 52-week low of $55.01 and a 52-week high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.